Egrifta (Tesamorelin) Regulatory Status: US, EU, Canada, UK

See the public record for Tesamorelin

  • US status / FDA-approved prescription drug since November 10, 2010 (BLA 022505) [1][2]
  • Current US labels / Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026 [2][3]
  • Approved US use / excess abdominal fat in HIV-infected adults with lipodystrophy only [2][3]
  • Boxed warning / none in the current Egrifta SV or Egrifta WR label [2][3]
  • FDA compounding lists / in no category of the safety-risk, state-licensed pharmacy or outsourcing-facility lists [4][5][6]
  • HHS peptide policy / not among the six peptides in the October 2026 draft enforcement-discretion policy [7][8]
  • Sport / WADA S2.2.4, prohibited at all times [9][10]

United States: approved, for one use

FDA approved tesamorelin acetate as Egrifta on November 10, 2010 as a new molecular entity under application BLA 022505 [1][2]. Drugs@FDA notes that the application began as a new drug application and was deemed a biologics license application on March 23, 2020 [1].

The only approved use is reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy [2][3]. The label states that long-term cardiovascular safety has not been established, that prescribers should consider the risk and benefit of continuing in patients who have not had a reduction in visceral adipose tissue, and that the drug is not indicated for weight loss management because it has a weight-neutral effect [2].

The two current US labels

Both labels are dated July 29, 2026 [2][3]. Egrifta SV is a 2 mg vial given as 1.4 mg, 0.35 mL of the reconstituted solution, injected subcutaneously into the abdomen once daily with rotating sites [2]. Egrifta WR is an 11.6 mg vial given as 1.28 mg (0.16 mL) once daily; one reconstituted vial supplies seven daily doses [3]. The labels state that the two are not substitutable [3]. No boxed warning appears in either current label [2][3].

Compounding status in the United States

Tesamorelin is not on FDA's list of bulk drug substances that may present significant safety risks when compounded (list content dated April 22, 2026), and it appears in no category of FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) or of FDA's list for outsourcing facilities (updated March 21, 2025), so FDA has made no category-based statement about compounding it [4][5][6].

The HHS draft enforcement-discretion policy for compounded peptides, filed October 28, 2026 as Federal Register document 2026-22192, names six peptides, BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500, and tesamorelin is not one of them [7][8]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [8].

WADA and sport

WADA's Prohibited List names tesamorelin in section S2.2.4 among growth hormone releasing factors, GHRH and its analogues [9]. It is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances [9]. It is on the 2026 List, in force since January 1, 2026, and stays on the 2027 List [9][10].

Scope: Canada, the EU and the UK

This page sets out the United States regulatory position only. The FDA approval described above is the regulatory decision it covers [1][2].

Is tesamorelin FDA-approved?
Yes. FDA approved tesamorelin acetate as Egrifta on November 10, 2010 under BLA 022505, for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [1][2]. The current labels are Egrifta SV and Egrifta WR, both dated July 29, 2026 [2][3].
Does Egrifta carry a boxed warning?
No boxed warning appears in the current Egrifta SV or Egrifta WR label [2][3]. The labeled warnings cover neoplasms, elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity reactions, injection-site reactions and increased mortality in acute critical illness [2].
Can tesamorelin be compounded in the US?
FDA has placed tesamorelin in no category of its compounding lists, including the list of bulk substances that may present significant safety risks, so it has made no category-based statement about compounding it [4][5][6]. The October 2026 HHS draft enforcement-discretion policy covers six other peptides, not tesamorelin, and compounded drugs are not FDA-approved [7][8].
Are Egrifta SV and Egrifta WR interchangeable?
No. The Egrifta SV dose is 1.4 mg from a 2 mg vial; the Egrifta WR dose is 1.28 mg from an 11.6 mg vial, and the labels state the two are not substitutable [2][3].
Is tesamorelin banned in sport?
Yes. WADA names tesamorelin in S2.2.4 among growth hormone releasing factors and prohibits it at all times, in and out of competition [9]. It is on the 2026 List and stays on the 2027 List [9][10].
Show all 10 referencesHide references
  1. Drugs@FDA: FDA-Approved Drugs.
  2. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  3. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. Official web page.
  8. Official web page.
  9. World Anti-Doping Agency.
  10. World Anti-Doping Agency.
Evidence overview for Egrifta (Tesamorelin) Regulatory Status: US, EU, Canada, UK